TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia.

Ochiiwa, Hiroaki; Ailiken, Guzhanuer; Yokoyama, Masataka; Yamagata, Kazuyuki; Nagano, Hidekazu; Yoshimura, Chihoko; Muraoka, Hiromi; Ishida, Keiji; Haruma, Tomonori; Nakayama, Akitoshi; Hashimoto, Naoko; Murata, Kazutaka; Nishimura, Motoi; Kawashima, Yusuke; Ohara, Osamu; Ohkubo, Shuichi; Tanaka, Tomoaki

Ochiiwa, Hiroaki; Ailiken, Guzhanuer; Yokoyama, Masataka; Yamagata, Kazuyuki; Nagano, Hidekazu; Yoshimura, Chihoko; Muraoka, Hiromi; Ishida, Keiji; Haruma, Tomonori; Nakayama, Akitoshi; Hashimoto, Naoko; Murata, Kazutaka; Nishimura, Motoi; Kawashima, Yusuke; Ohara, Osamu; Ohkubo, Shuichi; Tanaka, Tomoaki.

Affiliation

Ochiiwa H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan.
Ailiken G; Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
Yokoyama M; Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
Yamagata K; Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
Nagano H; Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
Yoshimura C; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan.
Muraoka H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan.
Ishida K; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan.
Haruma T; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan.
Nakayama A; Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
Hashimoto N; Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
Murata K; Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
Nishimura M; Division of Laboratory Medicine, Clinical Genetics and Proteomics, Chiba University Hospital, Chiba, 260-8670, Japan.
Kawashima Y; Department of Applied Genomics, Kazusa DNA Research Institute, Kisarazu, Chiba, 292-0818, Japan.
Ohara O; Department of Applied Genomics, Kazusa DNA Research Institute, Kisarazu, Chiba, 292-0818, Japan.
Ohkubo S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan. s-ohkubo@taiho.co.jp.
Tanaka T; Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan. tomoaki@restaff.chiba-u.jp.

Oncogene ; 40(7): 1217-1230, 2021 02.

Article de En | MEDLINE | ID: mdl-33420360

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Pyrimidines / Pyrroles / Leucémie aigüe myéloïde / Protéines proto-oncogènes c-myc / Protéines proto-oncogènes c-bcl-2 / Protéine NEDD8 Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Oncogene Sujet du journal: BIOLOGIA MOLECULAR / NEOPLASIAS Année: 2021 Type de document: Article Pays d'affiliation: Japon Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google